ArticleWellcome open research2017

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Jagdeep Nanchahal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.